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SELECTION OF THE MONTH 
Big Title: HCV treatment allows transplant deactivation of 1 in 3 patients 
 
Small title (Cirrhosis): Risk factors for chronicity of DILI 
 
LIVER REGENERATION 
A new marker for ductular reaction (DR) 
The keratins are intermediate filament proteins responsible for the structural integrity 
of epithelial cells and are subdivided into cytokeratins and hair keratins. The type I 
cytokeratins consist of acidic proteins which are arranged in pairs of heterotypic keratin 
chains. The type II cytokeratins consist of basic or neutral proteins which are arranged 
in pairs of heterotypic keratin chains co-expressed during differentiation of simple and 
stratified epithelial tissues. Two members of the cytokeratin subfamily, i.e., keratin, 
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type I cytoskeletal 19 (K19, encoded by KRT19) and keratin, type II cytoskeletal 7 (K7, 
encoded by KRT7) are used as markers of the regenerative liver response termed DR 
which consists of activated biliary epithelial cells and hepatic progenitor cells and 
correlates with liver disease severity. Guldiken et al. now show that keratin, type I 
cytoskeletal 23 (K23, encoded by KRT23) is a stress-inducible marker of both DR and 
severity of liver disease. Interestingly, K23 is expressed in response to the type I acute-
phase inducer interleukin (IL)-1 beta but not the type I inducer IL-6, suggesting some 
specificity. These results suggest that K23 may serve as a marker for DR.  
 
NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) 
Non-invasive diagnosis, association with cardiovascular events and 
aggravation by sleep apnea 
There is a clear need of optimizing non-invasive diagnosis of NAFLD. In this issue, 
Boursier et al. compared an array of blood fibrosis tests as well as liver stiffness 
measurement (LSM) by Fibroscan for the diagnosis of liver fibrosis and prognosis 
assessment in a large series of patients with biopsy-proven NAFLD. LSM and 
FibroMeter-V2G were the two best-performing tests in the cross-sectional study. Two 
fibrosis classifications were developed to precisely estimate the histological fibrosis 
stage using these two parameters. Importantly, the higher was the class of the fibrosis 
classification, the worse was the prognosis. This important clinical study shows that 
advanced liver fibrosis confers a worse prognosis in patients with NAFLD and that it 
can be accurately estimated by both LSM and novel serum markers. In another study 
in this issue, Targher et al. performed a meta-analysis to quantify the magnitude of 
the association between NAFLD (and NAFLD severity) and risk of cardiovascular 
disease (CVD) events. A total of 16 studies including 34,000 adult individuals and 
approximately 2,600 CVD outcomes over a median period of 7 years were included. 
Patients with NAFLD had a higher risk of fatal and/or non-fatal CVD events (OR: 1.64). 
Patients with more 'severe' NAFLD were also more likely to develop fatal and non-fatal 
CVD events (OR 2.58). This meta-analysis conforms that NAFLD is associated with 
an increased risk of fatal and non-fatal CVD events. At the clinical level, obesity-related 
obstructive sleep apnea (OSA) and nocturnal hypoxia are associated with NAFLD 
progression. Sundaram et al. studied if OSA/nocturnal hypoxia induced oxidative 
stress mediates this effect in adolescents. They found that the presence of 
OSA/hypoxia was associated with more severe fibrosis and urine markers of 
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oxidative stress. Moreover, markers of oxidative stress correlated with the degree of 
hypoxia. This study strongly suggests that OSA-associated hypoxia in young patients 
could exacerbate NAFLD by aggravating oxidative stress. Finally, this issue of the 
Journal includes a relevant study by Asgharpour et al., who develop an experimental 
model of NAASH-associated hepatocellular carcinoma (HCC). A stable isogenic 
cross between C57BL/6J (B6) and 129S1/SvImJ (S129) mice were fed a high fat diet 
with ad lib consumption of glucose and fructose. Following initiation of the obesogenic 
diet, mice sequentially also developed steatosis (4-8 weeks), NASH (16-24 weeks), 
progressive fibrosis (16 weeks onwards) and spontaneous HCC. Importantly, the 
HCC gene signature resembled the S1 and S2 human subclasses of HCC. This novel 
model represents a unique opportunity for preclinical studies in NAFLD-associated 
HCC.  
 
GENETIC LIVER DISEASES 
UDCA as potential therapy for autosomic liver-kidney polycystic diasease 
There are no effective pharmacological therapies for polycystic liver disease. 
Ursodeoxycholic acid (UDCA) attenuates experimental hepatic cystogenesis in vitro 
and in animal models of polycystic liver disease. On this background, D'Agnolo et al. 
conducted a multicenter randomized trial in symptomatic patients. Patients with 
symptomatic polycystic liver disease were randomly assigned to UDCA treatment (15-
20mg/kg/day) or no treatment for 24 weeks. Primary endpoint was proportional change 
in total liver volume. The study revealed that UDCA administration for 24 weeks did 
not reduce total liver volume in all patients advanced PLD, while it reduced it in the 
subset of patients with autosomal dominant polycystic liver-kidney disease. This 
results merit further studies with larger number of patients. 
 
HEPATITIS C VIRUS (HCV) INFECTION 
Minimal residual viremia under sofosbuvir-based treatment - A concern? 
Determining the time to first undetectable HCV RNA levels by close on-treatment 
monitoring of hepatitis C viremia was the corner stone for treatment individualization 
in the era of peg-interferon-based regimens. Whether viral kinetics measurement may 
be also of help to predict the risk of relapse under treatment with direct-acting antivirals 
(DAA) is unclear. In a network study of 3 European centers, Maasoumy et al. 
retrospectively correlated viral kinetics with treatment outcome in 298 patients with 
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HCV-genotypes 1-5 treated with sofosbuvir-based regimens. Although residual HCV 
RNA was frequently detected at later stages of therapy, and even in 20% of 
patients at the end of therapy, SVR-rates remained high in these patients and this 
feature was not predictive for treatment failure. Only in patients with HCV type 3 
receiving the less robust sofosbuvir plus ribavirin regimen, the relapse rate was high, 
if HCV RNA levels exceed 45 IU/mL at week 2. Hence, even when hepatitis C viremia 
persists on-treatment at low levels, therapy should not be extended as long as patients 
receive robust dual DAA regimens. 
 
HEPATITIS B VIRUS (HBV) 
Therapeutic HBV vaccination? – not reached yet! 
Hepatitis B virus (HBV) specific immune stimulation in patients under long-term 
nucleos(t)ide treatment (NUC) represents an interesting approach in order to increase 
HBsAg loss. GS-4774 is a heat-inactivated, yeast-based, T-cell vaccine that express 
HBsAg, hepatitis B core as well as X antigen, and in which the Sacchyaromyces 
cervisiae yeast component may act as a natural adjuvant, potentially allowing for new 
T-cell responses. In this controlled phase II "proof of concept study", Lok et al. 
randomized 178 patients with chronic HBV infection who were virally suppressed on 
an oral antiviral to continue NUC alone or receive NUC plus GS-4774 2, 10, or 40 yeast 
units subcutaneously every 4 weeks until week 20. GS-4774 was well tolerated, but 
did not provide significant reductions in serum HBsAg in virally suppressed 
patients with chronic hepatitis B and no patient experienced loss of serum HBsAg. 
Combination approaches with other agents, and evaluation in other populations of 
patients with HBV (i.e. treatment naive) are ongoing to determine if GS-4774 might 
have a therapeutic benefit. 
 
HEPATITIS DELTA VIRUS (HDV)  
Entry inhibition in chronic hepatitis D – a first step towards effective regimens?  
Since the first description of a modest and mostly transient antiviral effect of interferon-
based regimens in chronic hepatitis delta more than 20 years ago, no relevant 
improvement in the management of this most aggressive form of viral hepatitis has 
been achieved. In this issue, the pharmacokinetics as well as safety and efficacy of a 
novel HBV and HDV entry inhibitor, myrcludex B, was prospectively evaluated in two 
studies: first, an open first-in-human, phase I clinical trial in 36 healthy volunteers by 
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Blank A et al., and second, a phase Ib/IIa study in which 24 patients with chronic 
hepatitis delta were enrolled by Bogomolov P et al. Myrcludex B is a myristolated 
peptide of 47 amino acids derived from the preS1-domain of the HBV large surface 
protein that efficiently blocks entry of HBV and HDV. This specific inhibition of the 
essential hepatic HBV and HDV virus receptor led to a reduction in HDV RNA in 
all patients, and in 2 out of 8 patients under monotherapy and 5 out of 7 patients with 
combination therapy including peg-interferon HDV RNA became negative at treatment 
week 24. Longer follow-up is required to see the full effect of the compound and to 
judge its potential implications for the field. But so far, the data are encouraging, and 
do support further evaluation of myrcludex B in combination with peg-interferon in 
hepatitis B and D. 
 
HEPATITIS E VIRUS (HEV)  
Mechanisms of ribavirin resistance 
Ribavirin has demonstrated significant antiviral activity against acute and chronic 
hepatitis E virus (HEV) infection. However, nonresponse to ribavirin may occur and 
has been linked to certain viral variants potentially conferring resistance to ribavirin. In 
an elegant study, Neyts et al. provide new insights in the mechanisms involved in 
ribavirin resistance showing that certain mutations (Y1320H, K1383N and G1634R) 
in the viral polymerase (Y1320H, K1383N and G1634R), but also an insertion in 
the hypervariable region were associated with the ribavirin resistant phenotype, 
and also play a role for viral fitness and replication efficacy. These data are highly 
relevant to better understand ribavirin resistance and the mode of ribavirin action in 
HEV infection. 
 
HEPATOCELLULAR CARCINOMA (HCC) 
Alcohol increases the risk of HCC 
Whether alcohol intake increases the risk of complications in patients with HCV-related 
cirrhosis is debated. Vandenbulcke et al. addressed this question in a prospective 
observational study that enrolled 192 patients with compensated HCV-related 
cirrhosis. They now show that light-to-moderate alcohol intake increases the risk 
of HCC in patients with HCV-related cirrhosis. These findings strongly suggest 
that patients’ care should include measures to ensure abstinence. 
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TRANSPLANTATION 
HCV treatment allows transplant deactivation of 1 in 3 
The introduction of oral DAA’s has revolutionized the management of patients with 
HCV infection but the effect of HCV eradication using these drugs is unknown. Belli et 
al. analyzed the data of 103 HCV patients that were on the liver transplant waiting list 
in 11 transplant centers and treated with the oral DAAs. This important study showed 
at 1 in 3 patients could be deactivated and 1 in 5 patients could be delisted over 
a 60-week period. These results are very impressive but require more validation and 
establishing long term outcomes. 
 
DRUG INDUCED LIVER INJURY 
Identification of risk factors for chronicity in patients with DILI 
Some patients who develop DILI end up with chronic liver disease but the risk factors 
associated with this are unknown. Lucena et al. studied the Spanish Registry for DILI 
and made some novel and important observations. Their data suggest that about 8% 
patients with DILI will develop chronic liver disease and that the term ‘chronic DILI’ 
should be used when the patients continue to show enzyme abnormalities at 1 year. 
About a third of these patients will develop cirrhosis. The factors associated with 
chronicity are older age, the presence of dyslipidemia and more severe liver 
injury in month 2 after onset of DILI. Very importantly, they identify the use of statins 
as being associated with chronicity. 
 
CIRRHOSIS 
A novel approach to analysis of EEG for possible diagnosis of minimal HE 
The diagnosis of early grades of hepatic encephalopathy (HE) has been plagued with 
wide variability in the results of current tests, making it difficult to find clinically robust 
end-points and pathogenic mechanisms. Olesen et al. performed an important study 
focusing on variability of the EEG in cirrhotic patients. Although the variability of the 
EEG was lower in cirrhotic patients compared with controls, the data show a biphasic 
phenomenon in the cirrhotics. In patients with minimal HE, the variability was 
increased compared with the unimpaired cirrhotic patients whereas it was 
decreased in those with overt HE. The significance of this observation is unclear at 
present but provide provocative insight into the pathophysiological basis of HE. 
 
